CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

Hydroxychloroquine as post exposure prophylaxisWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation

Correlated Drug Terms (2)

Name (Synonyms) Correlation
drug803 Others(No intervention) Wiki 1.00
drug961 ResCure™ Wiki 1.00

Correlated MeSH Terms (5)

Name (Synonyms) Correlation
D003141 Communicable Diseases NIH 0.11
D011014 Pneumonia NIH 0.07
D007239 Infection NIH 0.07
D045169 Severe Acute Respiratory Syndrome NIH 0.06
D018352 Coronavirus Infections NIH 0.05

Correlated HPO Terms (1)

Name (Synonyms) Correlation
HP:0002090 Pneumonia HPO 0.07

There is one clinical trial.

Clinical Trials

1 A Study of Hydroxychloroquine as Post Exposure Prophylaxis for SARS-CoV-2(HOPE Trial)

There is no known definite treatment after exposure to SARS-CoV-2, but the some animal and clinical trials confirmed the efficacy of hydroxychloroquine (HCQ) or chloroquine against SARS-CoV-2. Thus, in this study, we aim to evaluate the efficacy and safety of hydroxychloroquine as post exposure prophylaxis for SARS-CoV-2. - Primary end point: comparison the rate of COVID-19 between PEP with HCQ and control group. - Secondary end point: Comparison of the rate of COVID-19 according to the contact level (time, place, degree of wearing personal protective equipment). - Safety comparison: Safety verification by identifying major side effects in the HCQ group."

NCT04330144 Contact Person From COVID-19 Confirmed Patient Drug: Hydroxychloroquine as post exposure prophylaxis Other: Others(No intervention)

Primary Outcomes

Description: After postexposure prophylaxis, the rate of COVID-19 conversion between two groups

Measure: The rate of COVID-19

Time: PCR test of COVID-19 at 14 days after the contact from confirmed case

No related HPO nodes (Using clinical trials)